Abstract
Dabigatran, a direct thrombin inhibitor, is the first oral alternative to warfarin for stroke prevention in atrial fibrillation. Dabigatran offers several potential advantages over warfarin including ease of dosing, fewer drug interactions, and the lack of required coagulation monitoring. However, its overall effectiveness and safety will depend upon appropriate patient selection. This article discusses factors that should be taken into account when considering dabigatran for patients with atrial fibrillation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
